Ranbaxy Laboratories: Ranbaxy Laboratories Ltd reply to clarification sought by the exchange

The Exchange has sought clarification from Ranbaxy Laboratories Ltd with respect to news article appearing on ET Now on December 03, 2014 titled 'Germany bars antibiotic drug from Ranbaxys Madhya Pradesh plant'

Ranbaxy Laboratories Ltd replied stating, 'The news item is misleading and we wish to clarify as follows in order to place it in the right perspective.

The development pertains to only the Companys cephalosporin injectable unit at Dewas in Madhya Pradesh. The European authorities along with those from Australia and Canada carried out an inspection in June 2014 of all the facilities in Dewas. Well before that time, the Company had decided, to stop producing cephalosporin injectables at Dewas. Since then, the agencies have approved all our facilities for manufacturing Dosage Forms and APIs (Active Pharmaceutical Ingredients) at Dewas including that for oral cephalosporins with the only exception of the cephalosporin injectable unit.

We wish to state that Ranbaxys decision to discontinue manufacture of Cephalosporin injectables would not have a significant impact on the business. Further, we wish to clarify that the current approvals cover all other facilities (Dosage Forms and APIs) at Dewas, including those producing penem API & injections and oral cephalosporins.'